Mainz Biomed NV (NASDAQ:MYNZ) Sees Large Increase in Short Interest

Mainz Biomed NV (NASDAQ:MYNZ) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 322,531 shares, an increase of 26.3% from the January 15th total of 255,354 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily volume of 562,319 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 562,319 shares, the short-interest ratio is presently 0.6 days. Currently, 3.6% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on MYNZ shares. Wall Street Zen upgraded Mainz Biomed to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reissued a “sell (e)” rating on shares of Mainz Biomed in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Mainz Biomed has an average rating of “Sell”.

Hedge Funds Weigh In On Mainz Biomed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its stake in shares of Mainz Biomed by 38.4% during the 3rd quarter. Armistice Capital LLC now owns 394,519 shares of the company’s stock worth $588,000 after purchasing an additional 109,519 shares in the last quarter. Cerity Partners LLC acquired a new stake in Mainz Biomed during the 4th quarter valued at $183,000. Finally, Steward Partners Investment Advisory LLC increased its position in Mainz Biomed by 200.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after buying an additional 20,000 shares in the last quarter.

Mainz Biomed Price Performance

NASDAQ MYNZ traded up $0.05 during mid-day trading on Monday, hitting $0.80. The stock had a trading volume of 55,052 shares, compared to its average volume of 388,489. The company has a 50 day simple moving average of $1.12 and a 200 day simple moving average of $1.36. The company has a market cap of $7.25 million, a price-to-earnings ratio of -0.01 and a beta of 0.26. Mainz Biomed has a 52-week low of $0.60 and a 52-week high of $6.66. The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44.

Mainz Biomed (NASDAQ:MYNZ) last posted its earnings results on Friday, September 26th. The company reported ($1.32) earnings per share for the quarter. The business had revenue of $0.14 million during the quarter. Equities analysts forecast that Mainz Biomed will post -23.6 EPS for the current fiscal year.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.